1. Wirahadikusumah Saleh, University of Uppsala, Sweden. Fermented Foods (1975).
  2. Yves Delatte. The uses of lactic acid bacteria in the Fur Industry. International Symposium on the Fur Industry York, UK (1985).
  3. Wirahadikusumah Saleh, University of Uppsala, Sweden. Development of lactic acid bacteria during Early Stages of Fermentation in Fish Silage (1971).
  4. H. Tauson, University of Uppsala, Sweden. Lactic acid bacteria in ration for mink in the lactation period (1982).
  5. Ecole Vétérinaire de Toulouse, France. Experiments on lactic acid bacteria on weaning piglets (1982).
  6. T. Yamaguchi, Y. Kuroda, M. Saito, T. Ebina, F. Hoshino and N. Ishida, Tohoku University School of Medicine, 19/01/1984. Immune Interferoni Production by TH69, a lyophilized preparation of S.faecalis in murine spleen cultures (1984).
  7. D. Iannello, L. Bonina, D. Delfino, M.C. Berlinghieri, M.R. Gismondo and P. Mastroeni. Messina University, Italy. Effect of oral administration of a variety of bacteria on depressed macrophage functions in tumor-bearing rats. Ann. Immunol.(Inst. Pasteur) 135 C, p. 345-352 (1984).
  8. Miyoshi Ikawa. Nature of the lipids of some lactic acid bacteria. J. Bacteriology Vol. 85, p. 772-781 (1963).
  9. G. H. Spray. Microbiological assay of folic acid activity in human serum. Jour. Microbiology,17 p. 660-665 (1953).
  10. G. Weeks, S. Wakil. Studies on the control of fatty acid metabolism.Journal of Biol. Chem.Vol. 245, 8, April 25, p. 1913-1921 (1970).
  11. Volker Rusch. Bacteriotherapy with Normal Intestinal S. faecalis vaccine in humans: Results of a double study. Microecology and Therapy Vol. 15, p. 313-318 (1985).
  12. V. Rusch, R.M. Hyde and T.D. Lucckey. Application of S. faecalis and E. coli oral vaccines in humans and animals. Prog. Fd. Nutr. Sci.Vol.7, p. 39-52 (1983).
  13. Yasuo Kawai. Effect of cellular extracts of Streptococci on hyperlipidemia in rats, rabbits and humans. Microecology and Therapy Vol. 14, p. 109-126 (1984).
  14. K. Ishihara & Y. Kawai. Hypocholesterolemically active substances of E. faecalis Kawai. Microecology and TherapyVol. 16, p. 75-79 (1985).
  15. D. Müting, R. Leimbeck, H. Jochen Flasshoff, V. Rusch. Bifidobacterium bifidum administration in humans: a controlled clinical study in liver cirrhosis. Microecology and TherapyVol. 16, p. 271-272 (1986).
  16. a) D. Müting, R. Leimbeck, H. J. Flasshoff. The effects of fortified viable Bifidobacterium bifidum on intestinal microbial ecology; a controlled clinical study in liver cirrhosis with portal hypertension. Microecology and TherapyVol.16, p. 287-295 (1986).
    b) C. Del Vecchio-Blanco, G. Ambrogio, D. Mattera, M. Coltorti. Effect of treatment with S. faecium on the blood ammonia curve following protein loading in subjects with hepatic cirrhosis. Institute of Medical Semiotics, University of Naples, Italy (1984).
  1. W. Heit, H. Heit, H. Rodt. The role of microflora in allogenic bone marrow transplantation. Microecology and Therapy Vol. 11, p. 141-147 (1981).
  2. N. R. Hall, A.L. Goldstein. Neurotransmitters and the Immune System in Psychoneuroimmunology. Ader R. Ed. Academic Press, NY (1981).
  3. I. R. Rowland, P. Grasso.Applied Microbiology 29 7 (1975).
  4. J. R. Williams et al. Participation of liver fractions and intestinal bacteria in the metabolism of N-hydroxy-N-2-Fluorenylacetamide in the rat. Biochem. Pharmacol.19 p.173-188 (1970).
  5. L. A. Wheeler, F.B. Soderberg, P. Goldman. Cancer Research35, 2962 (1975).
  6. H. H. Balfour Jr. Cytomegalovirus infections of the gastro-intestinal tract. Microecology and TherapyVol.15, p. 55-56 (1985).
  7. R. L. Penn, R. D. Maca, R. D. Berg. Leukemia promotes the translocation of indigenous bacteria from the gastro-intestinal tract to the mesenteric lymph node and other organs. Microecology and TherapyVol. 15, p. 85-91 (1985).
  8. Edward Balish. Intestinal Flora and Immunity. Microecology and TherapyVol. 16, p. 157-167 (1986).
  9. Animal model of Human Disease: Aleutian Disease. American Journal of PathologyVol. 71, No. 2, p. 345-348 (1973).
  10. L. E. Perryman, K. L. Bamks, T. C. Maguire. Lymphocyte abnomalities dans in Aleutian Disease virus infection of mink. Journal of Immunology Vol. 115, No. 1, p. 22-27 (1975).
  11. S. Ducluzeau & P. Raibaud. Les interactions bactériennes dans le tube digestif. Rev. sci. tech. Epiz., 8 (2), p.291-311 (1981).
  12. Van der Waaij. Antibiotic choice: the importance of colonization resistance. Chichester: research Studies Press (1983).
  13. C. E. Bayliss, H. K. Bradley, V. Alun Jones, et al. Some aspects of chronic microbial activity in irritable bowel syndrome associate with food intolerance. Ann. 1 st Super Sanita1986; 22, p. 959-64.
  14. D. A. Burks, A. T. Axon. Adhesive Escherichia Coli in inflammatory bowel disease and infective diarrhoea. Br. Med. J. 1988; 297, p. 102-04.
  15. R.W. Ebringer, D.R. Cawdwell, P. Cowling, et al. Sequential studies in ankylosing spondylitis. Association of klebsiella pneumoniae, with active disease. Ann. Rheum. Dis. 1979; 37, p. 145-51.
  16. J. O. Hunter. Hypothesis: Food allergy – or entero metabolic disorder? LancetVol. 338, August 24th, 1991, p.495-496.
  17. Christina M. Surawicz. Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Bet Practice & Research Clinical Gastroenterology Vol. 17, No. 5, p. 775-783 (2003).
  18. Lynne V. McFarland, PhD; Christina M Surawicz, MD; Richard N. Greenberg, et al. A Randomized Placebo-Controlled Trial of Saccharomyces boulardii in Combination with Standard Antibiotics for Clostridium difficile Disease. JAMAJune 22/29, 1994, Vol. 271, No 24.
  19. Gary W. Elmer, PhD; Christins M. Surawicz, MD; Lynne V. McFarland, Phd . Biotherapeutic Agents: A Neglected Intestinal and Vaginal Infections. JAMAMarch 20, 1996, Vol 275, No 11 p. 870-876.
  20. Yvan Vandenplas. Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part I: Bacteria. Clin Microbiol Infect 1999; 5 p. 299-307.
  21. Yvan Vandenplas. Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part II: Yeasts. Clin Microbiol Infect 1999; 5 p. 389-395.
  22. S. J. Klebanoff, S. L. Hillier, D. A Eschebach, A. M. Waltersdorph. Control of the Microbial Flora of the Vagina by H2O2 –Generating Lactobacilli. The Journal of Infectious Diseases1999; 164 p.94-100.
  23. Anders Hallén, MD, PhD, Connie Jarstrand, MD, PhD, and Calle Påhlson, MSc. Treatment of Bacterical Vaginosis with Lactobacilli. Reprint requests; Anders Hallén, MD, Department of Dermatology and Venereology, University Hospital, Akademiska sjukhuset, S-75185 Uppsala, Sweden. Received for publication November 19, 1990, revised May 28, 1991, and accepted May 31, 1991.
  24. Sharon L. Hillier, Marijane A. Krohn, Lorna K. Rabe, et al. The Normal Vaginal Flora, H2 O2 –Producing Lactobacilli, and Bacterial Vaginosis in Pregnant Women. Clinical Infectious Diseases 1993; 16(suppl. 4): p. 273-81.
  25. Frank A. M. Klaver, Roelof Van Der Meer. The Assumed Assimilation of Cholesterol by Lactobacilli and Bifidobacterium bifidum Is Due to Their Bile Salt-Deconjugating Activity. Applied Environmental MicrobiologyApr. 1993, Vol. 59, No. 4, p.1120-1124.
  26. Amal K. Mitra, Golam H. Rabbani. A Double-Blind, Controlled Trial of Bioflorin (Streptococcus faecium SF68) in adults With Acute Diarrhea Due to Vibrio cholerae and Enterotoxigenic Escherichia coli.Gastroentology1990; 99, p. 1149-1152.
  27. E. Camarri, A. Belvisi, G. Guidoni et al. A Double-Blind Comparison of Two Different Treatments for Acute Enteritis in Adults. Chemotherapy1981 Vol. 27, p. 466-470.
  28. Gaetano Bellomo, Antonio Mangiane, Luigi Nicastro, Giuliano Frigerio. A Controlled Double-Blind study of SF 68 strain as a Biological Preparation for the treatment of Diarrhoea in Pediatrics. Current Therapeutic ResearchVol. 28, No. 6, December 1980.
  29. E. J. Schiffrin, F. Rochat, H. Link-Amster, et al. Immunomodulation of Human Blood Cells Following the Ingestion of Lactic Acid Bacteria. J Dairy Sci78:491-497 (1995).
  30. Dr. J. N. Kenyon M.D. M.B. Ch.B., Y.G.A. Delatte. The therapeutic aspects and properties of lactic acid bacteria. November 1991, reviewed February 1992, private communication.
  31. K. A. van Hoeij-de Boer, J. Schrijver. The Ecology of the Intestine. Nutricia Reasearch Zoetermeer (1991).
  32. S. C Nannan Panday, E. J. Vollaard. Bacteriotherapy with Lactobacilli. Pharm. Weekbl.1993; 128(28); 807-15.
  33. M. Miettinen, J. Vuopio-Varkkila, K. Varkkila. Production of Tumor Necrosis Factor Alpha, Interleukin-6 and Interleukin-10 is induced by Lactic acid Bacteria. Infection and Immunity 1996 December; 64(12): p. 5403-5405.
  34. M. Borgia, N. Sepe, V. Brancato, R. Borgia. A Controlled Clinical Study on Strepcoccus Faecium Preparation For The Prevention of Side Reactions During Long-Term Antibiotic Treatment. Current therapeutic researchFebruary 1982 Vol. 31 No. 2.
  35. H. Link-Amster, F. Rochat, K. Y. Saudan, et al. Modulation of a Specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunology and Medical Microbiology10, p. 55-64 (1994).
  36. F. M. Driessen, R. De Boer. Fermented milks with selected intestinal bacteria: a healthy trend in new products. Neth. Milk Dairy J.43, p. 367-382 (1989).
  37. Hanne Hove, Inge Nordgaard-Andersen, Per BrØbech Mortensen. Effect of lactic acid bacteria on the intestinal production of lactate and short-chain fatty acids, and the absorption of lactose1-3.Am J Clin Nutr1994; 59:74-9.
  38. Eileen Hilton, MD; Henry D. Isenberg, PhD;p Phyllis Alperstein,et al. Ingestion of Yogurt Containing Lactobacillicus acidophilus as Prophylaxis for Candidal Vaginitis. Annals of Internal Medicine 1992; 116: 353-357
  39. Glenn E. Hatcher, Randall S. Lambrecht. Augmentation of Macrophage Phagocytic Activity by Cell-Free Extracts of Selected Lactic Acid-producing Bacteria. J Dairy Sci1993; 76: 2485-2492.
  40. S. E. Gilliand, D. K. Walker. Factors to Consider When Selecting a Culture of Lactobacillus acidophilus as a Dietary Adjunct to Produce a hypocholesterolemic Effect in Humans.J Dairy Sci1990; 73: 905- 911.
  41. C. Del Vecchio-Blanco, G. Ambrogio, D. Mattera et al. Influence du traitment par Streptococcus faecium (S.F. 68) sur la courbe ammoniémique de charge protéique chez sujets atteints de cirrhose hépatique.Méd. Et Hyg.1981; 39: 2387-2389.
  42. F. T. Black, P. L. Andersen, J. Ørskov, F. Ørskov, et al. Prophylactic Efficacy of Lactobacilli on Traveler’s Diarrhea.
  43. Hyung-Yong Kim, D. V. M., M. S., Heyong-Suk Bae, D.V.M.,M.S., Young-Jin Baek, Ph.D. In Vivo Antitumor Effects of Lactic Acid Bacteria on sarcoma 180 Mouse Lewis Lung Carcinoma. Journal of Korean Cancer Association23,2, June 1991.
  44. F. Black, K. Einarsson, A. Lidbeck, et al. Effect of Lactic Acid Producing Bacteria on the Human Intestinal Microflora during Ampicillin Treatment. Scand J Infect Dis 23: 247-254 1991.
  45. Frank A. M. Klaver, Roelof van der Meer. The Assumed Assimilation of Cholesterol by Lactobacilli and Bifidobacterium bifidum Is due to Their Bile Salt-Deconjugating Activity. Applied and Environmental MicrobiologyApr.1993 Vol. 59 No.4, p. 1120-1124.
  46. Meei-yn Lin, Dennis Savaiano, Susan Harlander. Influence of Nonfermented Dairy Products Containing Bacterial on Lactose Maldigestion in Humans. J Dairy Sci 74: 87-95 (1991).
  47. Jose M. Saavedra, Nancy A. Baumann, Irene Oung, et al. Feeding of Bifidobacterium Bifidum and Streptococcus Thermophilus to Infants in hospital for prevention of diarrhea and shedding of rotavirus. The LancetOctober 15, 1994 Vol.344 p.1046-1049.
  48. J. P. Buts, P. Bernasconi, C. Dive. Stimulation of secretory IgA and secretory component immunoglobulins in small interstine of rats treated with Saccharomyces boulardii. Dig Dis Sci.1990 Feb; 35(2):251-256.
  49. C. Pothoulakis, C. P. Kelly, M. A. Joshi, N. Gao, C. J. O´Keane, I. Castagliuolo, J. T. Lamont. Saccharomyces boulardii inhibits Clostridium difficile toxin: A binding and enterotoxicity in rat ileum. Gastroenterology1993 Apr;104(4): 1108-1115.
  50. I. Castagliuolo, M. F. Riegler, L. Valenik, J. T. Lamont, C. Pothoulakis. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.Infect Immun.1999 Jan; 67(1): 302-307.
  51. de Wit MA, A. M. Hoogenboom-Verdegaal, E. S. Goosen, M. J. Sprenger, M. W. Borgdorff. A population based longitudinal study on the incidence and disease burden of gastyroenteritis and Campylobacter and Salmonella infection in four regions of the Netherlands. Eur J Epidemiol.2000; 16(8): 713-718.
  52. Marcel Baumuller. Therapy of Ankle Joint Distortions with Hydrolytic Enzymes; Results of Double-Blind Clinical Trials. Allgemeinmedizin19: p.178-182 (1990).
  53. C. Steffen, J. Menzel. Enzymbbau von Immunkomplexen. Zeitschrift fir Rheumatologie42:p.249-255 (1983).
  54. Lucia Desser, Alexander Rehberger. Introduction of Tumor Necrosis Factor in Human Peripheral-Blood Mononuclear Cells by Proteolytic Enzymes. Oncology 47(6):p.475-477 (1990).
  55. N. J. Gonzales, L. L. Isaacs. Evaluation of Pancreatic Proteolytic Enzyme Treatment of Adenocarcinoma of the Pancreas, with Nutrition and Detoxification Support. Nutrition and Cancer33(2):p.117-124 (1999).
  56. Ottokar Rokitansky. Adjuvant Enzyme Treatment Before and After Breat Cancer Surgery. Dr. Med1(2):p.16 (1980).
  57. Friedrich-Wilhelm Dittmar. Enzymtherapie in der Gynakologi (Enzyme Treatment in Gynecology). Allgemein Medizin 19:p.1568-1569 (1990).
  58. L. B. Sheila, M. B. Glasg. Bromelain and the Cervix Uteri. Lancet2:p.1420-1422 (1960).
  59. S. E. Soule, H. C. Wasserman, R. Burstein. Oral Proteolutic Enzyme Therapy (Chymoral) in Episiotomy Patients. American Journal of Obstetrics and Gynecology95:p.820-823 (1966).
  60. E. Rammer and F. Friedrich. Enzyme Therapy in Treatment of Mastopathy. A Randomized Double-Blind Clinical Study. Wiener Klinische Wochenschrift108(6):p.180-183 (1996).
  61. N. F. Hanna, D. Taylor-Robinson, M. Kalodiki-Karamanoli et al. The relation between vaginal ph and the microbiological status in vaginitis. Brit. J. Obstet. Gynaecol., 92 p. 1267-1271 (1985).
  62. H. Minkiff, A. Grunebaum, J. Feldman et al. Relationship of vaginal ph and Papinicolaou smear results to vaginal flora and pregnancy outcome.Internatinal Journal of Gynecology & Obstetrics25, p.17-23 (1987).
  63. K.S. Moghissi. Vaginal fluid constituents. In Beller, F. K. and Schumacher, G. F. B. (eds) The biology of the fluids of the female genital tract. Elsevier, New York p. 13-23 (1979).
  64. T. A. Stamey, M. F. Kaufman. Studies of introital colonization in women with recurrent urinary infections. II. A comparison of growt in normal vaginal fluid of common versus uncommon serogroups of Escherichia coli. Journal of Urology,114, p. 264-267 (1975).
  65. L. Weinstein, M. Bogin, J. H. Howard, B. B. Finkelstone. A survey of the vaginal flora at various ages, with special reference to the doderlein bacillus. American Journal of Obstetrics & Gynecology32, p. 211-218 (1936).
  66. W. Konig. Enzymes therapy for virus infections and carcinoma. Acta Medica Emperica 1-9 (1991).
  67. V. Martynenko. Wobenzym in the Combined Pathogenetic Therapy of Chronic Urethrogenic Prostatitis. Lik. Sprava6:p.118-120 (August 1998); AND

A. R. Guskov, I. D. Bogacheva, and G. B. Iatsevich. Systemic (Vobenzyme Preparation) and Local Enzyme Therapy in Transurethral Drainage of the Prostate in Patients with Obstructive Forms of Chronic Prostatitis. Urol. Nefrol.6:p.37-42 (November/December 1998).

  1. S. A. Kenfield, M. J. Stampfer, E. Giovannucci, J. M. Chan. Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-Up Study. J Clin Oncol. (published ahead of print) doi:10.1200/JCO.2010.31.5226 (2011).
  2. G. Dalmasso, F. Cottrez, V. Imbert, P. Lagadec, J-F. Peyron, P. Rampal, D. Czerucka, H. Groux. Saccharomyces boulardii Inhibits Inflammatory Bowel Disease by Trapping T Cells in Mesenteric Lymph Nodes.Gastroeneterology131: 1812-1825 (2006).
  3. V. O. Oyetayo, F. C. Adetuyi, F. A. Akinyosoye. Safety and protective of Lactobacillus acidophilus and Lactobacillys casei used as probiotic agent in vivo. African Journal of Biotechnology Vol. 2 (11):p. 448-452 (Nov. 2003).
  4. R. S. Taylor, K. E. Ashton, T. Moxham, L. Hooper, S. Ebrahim. Reduced dietary salt for the prevention of cardiovascular Disease. Cochrane Database of Systematic Reviews, doi: 10.1002/14651858.CD009217 (2011).
  5. M. Lyte. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: Microbial endocrinology in the design and use of probiotics. Bioessays (published online ahead of print), doi: 10.1002/bies.201100024 (2011).
  6. A. Ouwehand, G. Leyer, D. Carcano.Probiotics Reduce Incidence and Duration of Respiratory Tract Infections in 3- to 5-year-old Children. Pediatrics121;S115 doi:10.1542/peds.2007-2022JJJ (2008).
  7. M. Tabbers, I de Milliano, M. G. Roseboom, M.A. Benning. Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutrition Journal(published ahead of print) doi: 10.1186/1475-2891-10-19 (2011).
  8. T. D. Braga, G. Alves Pontes da Silva, P. I. Cabral de Lira, M. de Carvalho Lima. Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial.American Journal of Clinical Nutrition, vol. 93, p. 81-86 (2011).
  9. R. Myhre, A. L. Brantsaeter, S. Myking, H. K. Gjessing, V. Sengpiel, H. M. Meltzer, M. Haugen, B. Jacobsson. Intake of probiotic food and risk of spontaneous preterm delivery. American Journal of Clinical Nutrition, vol. 93, p. 81-86 (2011).
  10. J. Rushing, J. Neu. Probiotics for pregnant women and preterm neonates. American Journal of Clinical Nutrition, vol. 93 , p. 3-4 (2011).
  11. A. Berggren, I. Lazou Ahren, N. Larsson, G. Onning. Randomized, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections.European Journal of Nutrition(published online before printing), doi: 10.1007/s00394-010-0127-6, (2010).
  12. S. Guandalini, G. Magazzu, A. Chiaro et al. VSL#3 Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Crossover Study. Journal of Pediatric Gastroenterology & Nutritionvol. 51, Issue 1, p. 24-30, doi: 10.1097/MPG.0b013e3181ca4d95, (2010).
  13. I. Hojsak, N. Snovak, S. Abdović, H. Szajewska, Z. Mišak, S. Kolače. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centres: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Nutritionvol. 29, issue 3, p. 312-316, (2009).
  14. H. Zaharoni, E. Rimon, H. Vardi, M. Friger, A. Bolotin, et al. Probiotics improve bowel movements in hospitalized elderly patients – The proage study. Journal of Nutrition,Health and Aging, vol. 15, number 3, p. 215-220 (2011).
  15. C. L. J. Karlsson, G. Molin, F. Fak, M.-L. Johansson Hagslatt, M. Jakesevic, A. Hakansson, B. Jeppsson, B. Westrom, S. Ahrne. Effects on weight gain and gut microbiota in rats given bacterial supplements and a high-energy-dense diet from fetal life through to 6 months of age.British Journal of Nutrition(published ahead of print), doi: 10.1017/S0007114511001036 (2011).
  16. R-C. Cody, C. Stanton, L. O’Mahony, R. Wall, F. Shanahan, E. M. Quigley, G. F. Fitzgerald, R. Paul Ross. Recombinant lactobacilli expressing linoleic acid isomerase can modulate the fatty acid composition of host adipose tissue in mice. Microbiology(published ahead of print) doi: 10.1099/mic.0.043406-0 (2010).
  17. Y. Kadooka, M. Sato, K. Imaizumi, A. Ogawa, K. Okuyama, Y. Akai, M. Okano, M. Kagoshima, T. Tsuchida. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. European Journal of Clinical Nutrition, vol. 64, number 6, p. 636-643 (2010).
  18. M. J. Ege et al. Exposure to environmental microorganisms and childhood asthma. The New England Journal of Medicine; 364, p. 701-709 (2011).
  19. J. E. Gern. Barnyard microbes and childhood asthma. The New England Journal of Medicine; 364, p. 769-770 (2011).
  20. B. L. K. Chawes et al. Elevated eosinophil protein X in urine from healthy neonates precedes development of atopy in the first 6 years of life. American Journal of Respiratory and Critical Care Medicine; doi: 10.1164/rccm.201101-0111OC (2011).
  21. P. Engel, G. Fagherazzi, S. Mesrani, M-C. Boutron-Ruault, F. Clavel-Chapelon. Joint effects of dietary vitamin D and sun exposure on breast cancer risk: results from the French E3N cohort. Cancer Epidemology, Biomarkers & Prevention (published online ahead of print) doi: 10.1158/1055-9965.EPI-10-1039.
  22. D. Mozaffarian et al. Trans-Palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. Adults. Annals of Internal Medicine; 153, p. 790-799 (2010).
  23. C. A. Rivera, L. Gaskin, G. Singer, J. Houghton, M. Allman. Western diet enhances hepatic inflammation in mice exposed to cecal ligation and puncture. BMC Physiology, doi: 10.1186/1472-6793-10-20 (2010).
  24. J. L. Benjamin et al. No clinical benefit of prebiotics in the treatment of active Crohn’s Disease: A double-blind, randomised, placebo-controlled trial. Digestive Disease Week, absract T2020 (2010).
  25. S. F. Keller, A. McCartney, G. Gibson. Bacillus coagulans as a probiotic. Food and Science Technology Bulletin, doi:10.1616/1476-2137.16015 (2010).
  26. E. Stamatakis et al. Screen-based entertainment time, all-cause mortality, and cardiovascular events. Journal of the American College of Cardiology; 57, p. 292-299 (2011).
  27. T. J. Kaptchuk et al. Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS One; 5: e15591 (2010).
  28. E. M. R. Clayton et al. The impact of bisphenol A and triclosan on immune parameters in the US population, NHANES 2003-2006. Environmental Health Pespectives, doi: 10.1289/ehp.1002883 (2010).
  29. J. Adams, R. Tyrell, M. White. Do television food advertisements portray advertised foods in a ‘healthy’ food context?. British Journal of Nutrition, doi: 10.1017/S0007114510004435 (2010).
  30. L. Grzeskowiak, E. Isolauri, S. Salminen, M. Gueimonde. Manufacturing process influences properties of probiotic bacteria. British Journal of Nutrition(publishes ahead of print) doi: 10.1017/S0007114510004496 (2010).
  31. B. Arribas, N. Garrido-Mesa, L. Peran, D. Camuesco, M. Comalada et al. The immunomodulatory properties of viable Lactobacillus salivarius ssp. Salivarius CECT5713 are not restricted to the large intestine. European Journal of Nutrition (published online ahead of print) doi: 10.1007/s00394-011-0221-4 (2011).
  32. R. J. Bloomer, R.E. Canale, S. Suvarnapathki. Effect of oral intake of capsaicinoid beadlets on catecholamine secretion and blood markers of lipolysis in healthy adults: a randomized, placebo controlled, double-blind, cross-over study. Lipids in Health and Disease, 9:72, doi: 10.1186/1476-511X-9-72 (2010).
  33. J. Waynberg. Contributionsto the clinical validation of the traditional use of Phychopetalum Guyanna. 1stInternational Congress of Ethnopharmacology, Strasbourg, Francem June 5-9, 1990.
  34. J. Waynberg. Male sexual asthenia interest in a traditional plant derived medication. Ethnopharmacology, March 1995.
  35. P. Munoz, E. Bouza, M. Cuenca-Estrella et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis2005;40: 1625-34.
  36. H. Szajewska, J. Mrukowicz. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther2005; 22:365-72.
  37. M. Can, B. A. Besirbellioglu, I- Y. Avci et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Med Sci Monit 2006; 12:PI19-22.
  38. M. Guslandi, P. Giollo, P. A. testoni. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15:697-8.
  39. M. Guslandi, G. Mezzi, M. Sorghi, P. A. Testoni. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Did Dis Sci2000; 45: 1462-4.
  40. L. V. McFarland. Meta-analysis of probiotica for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-22.
  41. P. Marteau, P. Seksik. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004; 38:S67-9.
  42. S. P. Borriello, W. P. Hammes, W. Holzapfel et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis2003; 36:775-80.
  43. F. Cremonini, S. Di Caro, M. Covino et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol2002; 97:2744-9.
  44. J. Muller, N. Remus, K. H. Harms. Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses 1995; 38:119-23.
  45. H. Verstraelen, R. Verhelst, G. Claeys, M. Temmerman, M. Vaneechoutte. Culture-independent analysis of vaginal microflora: The unrecognized association of Atopobium vaginae with bacterial vaginosis. American Journal of Obstetrics and Gynecology 2004; 191:1130-2.
  46. L. Kwok, A. Stapleton, W. Stamm, S. Hillier, C.Wobbe, K. Gupta. Adherence of Lactobacillus crispatus to Vaginal Epithelial Cells From Women With or Without History of Recurrent Uninary Tract Infection. The Journal of Urology 2006; Vol. 176; 2050-2054.
  47. World Gastroenterology Organisation Practice Guideline: Probiotics and prebiotics. May 2008.
  48. Lefevre M, Racedo SM, Ripert G, Housez B, Cazaubiel M, Maudet C, Jüsten P, Marteau P et al. Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immunity & Ageing 2015, 12:24 (3 December 2015).

Biolatte Oy, VARKKAKUJA 2, FI-20320 TURKU, Tel. +358 (0)400-741 665

Copyright © 2022 Biolatte Oy. All Rights Reserved.